Top

Diabetology & Metabolic Syndrome

Published in:

Open Access 01-12-2023 | Insulins | Research

Efficacy and safety of basal-bolus insulin at 1:1.5 ratio compared to 1:1 ratio using a weight-based initiation and titration (WIT2) algorithm in hospitalized patients with type 2 Diabetes: a multicenter, randomized, clinical study

Authors: Xiaodan Zhang, Dewen Yan, Tao Du, Yunjuan Zhao, Jiangong Zhang, Tong Zhang, Mingrun Lin, Yanli Li, Wangen Li

Published in: Diabetology & Metabolic Syndrome | Issue 1/2023

Abstract

Background

Most studies initiated basal-bolus insulin in a ratio of 1:1 and titrated based on glucose. This study aimed to investigate the effectiveness and safety of a weight-based and ratio of 1:1.5 basal-bolus insulin using an algorithm for both initiation and titration in hospitalized patients with type 2 diabetes (T2D).

Methods

Hospitalized patients with T2D were randomly assigned to two groups in equal numbers to receive 1:1.5 and 1:1 ratios of basal-bolus insulin using a weight-based algorithm for both initiation and titration. The primary outcome was the time taken to reach the fasting blood glucose (FBG) target and 2-h postprandial blood glucose (2hBG) targets after three meals. The secondary outcome included insulin dosage to achieve glycemic control and the incidence of hypoglycemia during hospitalization.

Results

250 patients were screened between October 2021 and June 2022, 220 were randomly grouped, and 182 completed the trial (89 in the 1:1.5 and 93 in the 1:1 groups). The time taken to reach FBG targets was comparable between the two groups (3.4 ± 1.7 vs. 3.0 ± 1.3 days, p = 0.137) within about 3 days. The 2hBG after three meals was shorter in the 1:1.5 group than in the 1:1group (2.9 ± 1.5 vs. 3.4 ± 1.4 days, p = 0.015 for breakfast, 3.0 ± 1.6 vs. 3.6 ± 1.4 days, p = 0.005 for lunch, and 3.1 ± 2.1 vs. 4.0 ± 1.5 days, p = 0.002 for dinner). No significant difference in insulin dosages was found between the two groups at the end of the study. The incidence of hypoglycemia was similar in both groups.

Conclusions

We demonstrated that fixed dose-ratio basal-bolus insulin at 1:1.5 calculated using a weight-based initiation and titration algorithm was simple, as effective, and safe as ratio at 1:1 in managing T2D in hospitalized patients.

Trial Registration ChiCTR 2,100,050,963. Date of registration: September 8, 2021.

Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an Independent marker of in-hospital mortality in patients with undiagnosed Diabetes. J Clin Endocrinol Metab. 2002;87(3):978–82. https://doi.org/10.1210/jcem.87.3.8341.CrossRefPubMed

Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38. https://doi.org/10.1210/jc.2011-2098.CrossRefPubMed

American Diabetes Association. Economic costs of Diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–46. https://doi.org/10.2337/dc12-2625.CrossRefPubMedCentral

Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American association of clinical endocrinologists; American diabetes association. American association of clinical endocrinologists and American diabetes association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31. https://doi.org/10.2337/dc09-9029.CrossRefPubMedPubMedCentral

Migdal AL, Fortin-Leung C, Pasquel F, Wang H, Peng L, Umpierrez GE. Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 Diabetes: who can slide? J Hosp Med. 2021;16(8):462–8. https://doi.org/10.12788/jhm.3654.CrossRefPubMedPubMedCentral

Sadhu AR, Patham B, Vadhariya A, Chikermane SG, Johnson ML. Outcomes of real-world insulin strategies in the management of hospital hyperglycemia. J Endocr Soc. 2021;5(8):bvab101. https://doi.org/10.1210/jendso/bvab101.CrossRefPubMedPubMedCentral

Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized Study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 Diabetes. Diabetes Care. 2013;36(8):2169–74. https://doi.org/10.2337/dc12-1988.CrossRefPubMedPubMedCentral

Vellanki P, Bean R, Oyedokun FA, Pasquel FJ, Smiley D, Farrokhi F, et al. Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 Diabetes. Diabetes Care. 2015;38(4):568–74. https://doi.org/10.2337/dc14-1796.CrossRefPubMedPubMedCentral

Vellanki P, Cardona S, Galindo RJ, Urrutia MA, Pasquel FJ, Davis GM, et al. Efficacy and safety of intensive versus nonintensive supplemental insulin with a basal-bolus insulin regimen in hospitalized patients with type 2 Diabetes: a randomized clinical study. Diabetes Care. 2022;45(10):2217–23. https://doi.org/10.2337/dc21-1606.CrossRefPubMedPubMedCentral

10.

Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 Diabetes. Diabetes Care. 2015;38(12):2211–6. https://doi.org/10.2337/dc15-0160.CrossRefPubMedPubMedCentral

11.

Pérez-Belmonte LM, Osuna-Sánchez J, Millán-Gómez M, López-Carmona MD, Gómez-Doblas JJ, Cobos-Palacios L, et al. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac Surgery patients with type 2 Diabetes in a real-world setting: Lina-Surg study. Ann Med. 2019;51(3–4):252–61. https://doi.org/10.1080/07853890.2019.1613672.CrossRefPubMedPubMedCentral

12.

Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81(2):442–8. https://doi.org/10.1172/JCI113339.CrossRefPubMedPubMedCentral

13.

Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 Diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181–6. https://doi.org/10.2337/dc07-0295.CrossRefPubMed

14.

Meyer C, Boron A, Plummer E, Voltchenok M, Vedda R. Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 Diabetes: a randomized double-blind study. Diabetes Care. 2010;33(12):2496–501. https://doi.org/10.2337/dc10-0957.CrossRefPubMedPubMedCentral

15.

Pasquel FJ, Lansang MC, Khowaja A, Urrutia MA, Cardona S, Albury B, et al. A randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and Surgery patients with type 2 Diabetes: glargine U300 hospital trial. Diabetes Care. 2020;43(6):1242–8. https://doi.org/10.2337/dc19-1940.CrossRefPubMedPubMedCentral

16.

Zhang X, Zhang T, Xiang G, Wang W, Li Y, Du T, et al. Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 Diabetes: a multicenter, randomized, clinical study. BMJ Open Diab Res Care. 2020;8(1):e001261. https://doi.org/10.1136/bmjdrc-2020-001261.CrossRefPubMedPubMedCentral

17.

Liu L, Ke W, Wan X, Zhang P, Cao X, Deng W, et al. Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 Diabetes and its association with long-term glycemic remission. Diabetes Res Clin Pract. 2015;108(2):250–7. https://doi.org/10.1016/j.diabres.2015.02.011.CrossRefPubMed

18.

Bueno E, Benitez A, Rufinelli JV, Figueredo R, Alsina S, Ojeda A, et al. BASAL-BOLUS regimen with insulin analogues versus human insulin in medical patients with type 2 Diabetes: a randomized controlled trial in Latin America. Endocr Pract. 2015;21(7):807–13. https://doi.org/10.4158/EP15675.OR.CrossRefPubMed

19.

Li X, Du T, Li W, Zhang T, Liu H, Xiong Y. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 Diabetes: a randomized, controlled study. Clin Ther. 2014;36(9):1269–75. https://doi.org/10.1016/j.clinthera.2014.06.032.CrossRefPubMed

20.

Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 Diabetes. Clin Pharmacokinet. 2017;56(5):551–9. https://doi.org/10.1007/s40262-017-0514-8.CrossRefPubMedPubMedCentral

21.

Yang W, Liu J, Shan Z, Tian H, Zhou Z, Ji Q, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 Diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014;2(1):46–55. https://doi.org/10.1016/S2213-8587(13)70021-4.CrossRefPubMed

22.

https://www.hopkinsmedicine.org/endocrinology_diabetes_metabolism/_documents/Total_Daily_Insulin_Dose_and_JHH_Formulary_Insulins.pdf (hopkinsmedicine.org). Accessed 29 Nov 2022.

23.

Cook CB, Castro JC, Schmidt RE, Gauthier SM, Whitaker MD, Roust LR, et al. Diabetes care in hospitalized noncritically ill patients: more evidence for clinical inertia and negative therapeutic momentum. J Hosp Med. 2007;2(4):203–11. https://doi.org/10.1002/jhm.188.CrossRefPubMed

24.

Wexler DJ, Shrader P, Burns SM, Cagliero E. Effectiveness of a computerized insulin order template in general medical inpatients with type 2 Diabetes: a cluster randomized trial. Diabetes Care. 2010;33(10):2181–3. https://doi.org/10.2337/dc10-0964.CrossRefPubMedPubMedCentral

25.

Helmle KE, Chacko S, Chan T, Drake A, Edwards AL, Moore GE, et al. Knowledge translation to optimize adult inpatient glycemic management with basal bolus insulin therapy and improve patient outcomes. Can J Diabetes. 2018;42(5):505–13. https://doi.org/10.1016/j.jcjd.2017.12.010.CrossRefPubMed

26.

Neubauer KM, Mader JK, Höll B, Aberer F, Donsa K, Augustin T, et al. Standardized glycemic management with a computerized workflow and decision support system for hospitalized patients with type 2 Diabetes on different wards. Diabetes Technol Ther. 2015;17(10):685–92. https://doi.org/10.1089/dia.2015.0027.CrossRefPubMedPubMedCentral

27.

Mathioudakis N, Jeun R, Godwin G, Perschke A, Yalamanchi S, Everett E, et al. Development and implementation of a sbcutaneous insulin clinical decision support tool for hospitalized patients. J Diabetes Sci Technol. 2019;13(3):522–32. https://doi.org/10.1177/1932296818798036.CrossRefPubMed

28.

Toyoshima MTK, Brandes PHR, da Paz Lauterbach G, Moraes JRA, de Paiva EF, Umpierrez GE, et al. Insulin APP application protocol for the inpatient management of type 2 Diabetes on a hospitalist-managed ward: a retrospective study. Arch Endocrinol Metab. 2022;66(4):498–505. https://doi.org/10.20945/2359-3997000000496.CrossRefPubMed

29.

Galindo RJ, Davis GM, Fayfman M, Reyes-Umpierrez D, Alfa D, Peng L, et al. Comparison of efficacy and safety of glargine and detemir insulin in the management of inpatient hyperglycemia and diabetes. Endocr Pract. 2017;23(9):1059–66. https://doi.org/10.4158/EP171804.OR.].CrossRefPubMedPubMedCentral

30.

Galindo RJ, Pasquel FJ, Vellanki P, Alicic R, Lam DW, Fayfman M, et al. Degludec hospital trial: a randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 Diabetes. Diabetes Obes Metab. 2022;24(1):42–9. https://doi.org/10.1111/dom.14544.CrossRefPubMed

31.

Suzuki J, Yamakawa T, Oba M, Nagakura J, Shigematsu E, Tamura H, et al. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 Diabetes: an open-label, randomized controlled study. Endocr J. 2019;66(11):971–82. https://doi.org/10.1507/endocrj.EJ18-0309.CrossRefPubMed

32.

Leahy JL. Insulin management of diabetic patients on general medical and surgical floors. Endocr Pract. 2006;12(Suppl 3):86–90. https://doi.org/10.4158/EP.12.S3.86.CrossRefPubMed

33.

Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. RAndomized study of basal Bolus insulin therapy in the inpatient management of patients with type 2 Diabetes undergoing general Surgery (RABBIT Surgery). Diabetes Care. 2011;34(2):256–61. https://doi.org/10.2337/dc10-1407.CrossRefPubMedPubMedCentral

34.

Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 Diabetes: basal plus trial. Diabetes Care. 2013;36(8):2169–74. https://doi.org/10.2337/dc10-1407.CrossRefPubMedPubMedCentral

35.

Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, et al. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicentre randomized clinical trial. Diabetes Obes Metab. 2019;21(4):837–43. https://doi.org/10.1111/dom.13587.CrossRefPubMed

36.

Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 Diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753–60. https://doi.org/10.1016/S0140-6736(08)60762-X.CrossRefPubMed

Title: Efficacy and safety of basal-bolus insulin at 1:1.5 ratio compared to 1:1 ratio using a weight-based initiation and titration (WIT2) algorithm in hospitalized patients with type 2 Diabetes: a multicenter, randomized, clinical study
Authors: Xiaodan Zhang
Dewen Yan
Tao Du
Yunjuan Zhao
Jiangong Zhang
Tong Zhang
Mingrun Lin
Yanli Li
Wangen Li
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Insulins
Insulins
Type 2 Diabetes
Hypoglycemia
Published in: Diabetology & Metabolic Syndrome / Issue 1/2023
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-023-01193-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Biomarkers of obesity-mediated insulin resistance: focus on microRNAs

Mortality prediction in patients with hyperglycaemic crisis using explainable machine learning: a prospective, multicentre study based on tertiary hospitals

Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis

Comparison of fasting and random lipid profiles among subjects with type 2 diabetes mellitus: an outpatient-based cross-sectional study in Bangladesh

Cervical and ocular vestibular evoked myogenic potentials in patients with Diabetic Peripheral Neuropathy

Ten-year risk assessment for cardiovascular diseases using ASCVD risk estimator plus: outcomes from hypertension and diabetes patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials